Evidence map›Paper›PMID 24556869›Full record

ArticleAIDS (London, England)2014

Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy.

Margaret T May, Mark Gompels, Valerie Delpech, Kholoud Porter, Chloe Orkin, Stephen Kegg, Phillip Hay, Margaret Johnson, Adrian Palfreeman, Richard Gilson and 13 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIDS (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02596334 (Randomized Clinical Trial to Evaluate the Efficacy of a Dolutegravir Monotherapy), which is not on this map. Cited by 303 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
303citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02596334 phase3terminatednot on this mapstarted 2015, after this paper: background citation

Randomized Clinical Trial to Evaluate the Efficacy of a Dolutegravir Monotherapy (Tivicay®) Versus the Maintenance of a Successful Triple Therapy Using Abacavir + Lamivudine + Dolutegravir (Triumeq®) in HIV-1- Infected Patients

TypeinterventionalSponsorCentre Hospitalier Régional d'OrléansRan2015 to 2018Enrolled158ConditionsHIVArmsdolutegravir 50mg +abacavir 600mg +lamivudine 300mg, dolutegravir
3 · Its place in the literature

Who cites it

303 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Article
  20. Article

243 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Margaret T MayaUniversity of Bristol bNorth Bristol NHS Trust, Bristol cPublic Health England dMedical Research Council Clinical Trials Unit eBarts and The London NHS Trust fSouth London Healthcare NHS Trust gSt George's Healthcare NHS Trust hRoyal Free Hampstead NHS Trust, London iUniversity Hospitals of Leicester NHS Trust, Leicester jMortimer Market Centre, University College Medical School, London kSouth Tees Hospital NHS Foundation Trust, Middlesbrough lYork Teaching Hospital NHS Foundation Trust, York mResearch Department of Infection & Population Health, UCL nImperial College Healthcare NHS Foundation Trust oKings College Healthcare NHS Foundation Trust and Kings College London, London pBrighton and Sussex University Hospitals NHS Trust, Brighton qNorth Middlesex University Hospital NHS Trust, London rThe Lothian University Hospitals NHS Trust, Edinburgh sChelsea and Westminster NHS Foundation Trust tHomerton University Hospital NHS Trust, London, UK.
Mark Gompels
Valerie Delpech
Kholoud Porter
Chloe Orkin
Stephen Kegg
Phillip Hay
Margaret Johnson
Adrian Palfreeman
Richard Gilson
David Chadwick
Fabiola Martin
Teresa Hill
John Walsh
Frank Post
Martin Fisher
Jonathan Ainsworth
Sophie Jose
Clifford Leen
Mark Nelson
Jane Anderson
Caroline Sabin
UK Collaborative HIV Cohort (UK CHIC) Study

Funding

Medical Research Council G0000199Medical Research Council G0600337Medical Research Council G0700820Medical Research Council G0900274Medical Research Council MC_UU_12023/15Medical Research Council MR/J002380/1
6 · The paper itself

Abstract

objectiveThe objective of this study is to estimate life expectancies of HIV-positive patients conditional on response to antiretroviral therapy (ART).

methodsPatients aged more than 20 years who started ART during 2000-2010 (excluding IDU) in HIV clinics contributing to the UK CHIC Study were followed for mortality until 2012. We determined the latest CD4 cell count and viral load before ART and in each of years 1-5 of ART. For each duration of ART, life tables based on estimated mortality rates by sex, age, latest CD4 cell count and viral suppression (HIV-1 RNA <400 copies/ml), were used to estimate expected age at death for ages 20-85 years.

resultsOf 21 388 patients who started ART, 961 (4.5%) died during 110 697 person-years. At start of ART, expected age at death [95% confidence interval (CI)] of 35-year-old men with CD4 cell count less than 200, 200-349, at least 350 cells/μl was 71 (68-73), 78 (74-82) and 77 (72-81) years, respectively, compared with 78 years for men in the general UK population. Thirty-five-year-old men who increased their CD4 cell count in the first year of ART from less than 200 to 200-349 or at least 350 cells/μl and achieved viral suppression gained 7 and 10 years, respectively. After 5 years on ART, expected age at death of 35-year-old men varied from 54 (48-61) (CD4 cell count <200 cells/μl and no viral suppression) to 80 (76-83) years (CD4 cell count ≥350 cells/μl and viral suppression).

conclusionSuccessfully treated HIV-positive individuals have a normal life expectancy. Patients who started ART with a low CD4 cell count significantly improve their life expectancy if they have a good CD4 cell count response and undetectable viral load.

Indexed as

Life ExpectancyAdultAgedAged, 80 and overAnti-Retroviral AgentsCD4 Lymphocyte CountFemaleHIV-1HIV InfectionsHumansMaleMiddle AgedTreatment OutcomeUnited KingdomViral LoadYoung AdultAnti-Retroviral Agents

Identifiers

PMID24556869
PMCPMC4004637

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.